GT201000080A - Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
GT201000080A
GT201000080A GT201000080A GT201000080A GT201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A
Authority
GT
Guatemala
Prior art keywords
benzimidazol
crystal form
carboxamida
pirrolidin
methyl
Prior art date
Application number
GT201000080A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence Kolaczkowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000080A publication Critical patent/GT201000080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GT201000080A 2007-10-12 2010-04-09 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida GT201000080A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
GT201000080A true GT201000080A (es) 2012-04-03

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000080A GT201000080A (es) 2007-10-12 2010-04-09 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20160039312A (enExample)
CN (2) CN105367554A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2562081T3 (es) 2007-10-12 2016-03-02 Abbvie Bahamas Ltd. Forma cristalina 2 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida
PL2722046T3 (pl) 2007-10-12 2017-06-30 Abbvie Ireland Unlimited Company Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
WO2017152846A1 (zh) * 2016-03-09 2017-09-14 苏州晶云药物科技有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ES2562081T3 (es) * 2007-10-12 2016-03-02 Abbvie Bahamas Ltd. Forma cristalina 2 de 2-((R)-2-metilpirrolidin-2-il)-1H-bencimidazol-4-carboxamida
PL2722046T3 (pl) 2007-10-12 2017-06-30 Abbvie Ireland Unlimited Company Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu

Also Published As

Publication number Publication date
US20140024838A1 (en) 2014-01-23
US8835647B2 (en) 2014-09-16
TWI422588B (zh) 2014-01-11
BRPI0816221A2 (pt) 2015-06-16
CA3006332A1 (en) 2009-04-16
US8372987B2 (en) 2013-02-12
UA113277C2 (xx) 2017-01-10
MX350019B (es) 2016-12-09
KR20160039312A (ko) 2016-04-08
CN105367554A (zh) 2016-03-02
BRPI0816221A8 (pt) 2015-09-22
RU2012147692A (ru) 2014-05-20
PA8798401A1 (es) 2009-05-15
NZ583209A (en) 2012-06-29
US20130123317A1 (en) 2013-05-16
US20150148392A1 (en) 2015-05-28
ES2620299T3 (es) 2017-06-28
WO2009049111A1 (en) 2009-04-16
RU2476434C2 (ru) 2013-02-27
CA2696424A1 (en) 2009-04-16
AU2008310781B2 (en) 2013-03-28
PT2722046T (pt) 2017-03-15
ECSP10010150A (es) 2010-06-29
JP2019001811A (ja) 2019-01-10
SG185297A1 (en) 2012-11-29
KR20100090769A (ko) 2010-08-17
US9580410B2 (en) 2017-02-28
CN101821270A (zh) 2010-09-01
UA101961C2 (xx) 2013-05-27
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
ZA201002090B (en) 2011-11-30
PL2722046T3 (pl) 2017-06-30
JP2014237659A (ja) 2014-12-18
CA2696424C (en) 2018-07-10
CR11368A (es) 2010-10-25
MX2010003772A (es) 2010-04-21
DOP2010000099A (es) 2017-04-30
RU2010116397A (ru) 2011-11-20
EP2722046A1 (en) 2014-04-23
JP2011500589A (ja) 2011-01-06
CO6280493A2 (es) 2011-05-20
EP2722046B1 (en) 2016-12-21
MY156691A (en) 2016-03-15
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2017071618A (ja) 2017-04-13
DK2722046T3 (en) 2017-03-20
AU2008310781A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
GT201000080A (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
CU20110052A7 (es) Compuestos orgánicos
UY32730A (es) Inhibidores de cyp17
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
NI201200023A (es) Derivados de 5-fluoropirimidinona
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PA8809001A1 (es) Compuestos organicos
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MA32938B1 (fr) Composes organiques
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP099818A (es) Procesos para la preparacion de pirazoles
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP15032859A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboxilato
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CO6310993A2 (es) Moleculas utiles para el control de insectos
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона